Myocardial Infarction Market Size is projected to reach USD 3.85 billion by 2030, growing at a CAGR of 8%: Straits Research

New York, United States, March 07, 2023 (GLOBE NEWSWIRE) — Myocardial Infarction or heart attack is a condition when blood flow at a heart muscle stops or decreases. The condition may occur due to various reasons, including excessive smoking, unhealthy food habits, and others. It is more common in elderly people and may lead to death. Many treatment methods are available for the condition including various types of drugs and drug classes, surgeries, and others. All the treatment methods may differ from individual to individual. High chances of reoccurrence are the major factors leading to the increasing usage of prevention and treatment drugs.

Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/myocardial-infarction-market/request-sample

Increasing research and development activities for safe drug development

Increasing research and development activities and growing technological advancements by various companies and government organizations are creating lucrative opportunities for market players. Various companies are emphasizing on developing innovative drugs. For instance, Novartis has developed a drug called canakinumab (ACZ885). It helps to prevent heart attacks by controlling inflammation—a different approach than lowering cholesterol level. According to Novartis, it reduced the cardiovascular risk by 25% in the trial presented at American Heart Association Session 2017.

Report Scope

Report Metric	Details
Market Size	USD 3.85 billion by 2030
CAGR	8% (2023-2031)
Historical Data	2019-2020
Base Year	2021
Forecast Period	2022-2030
Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Product Type, Distribution Channel
Geographies Covered	North America, Europe, Asia-Pacific, LAME, and Rest of the World
Key Companies Profiled/Vendors	Apotex Inc., AstraZeneca, Bayer AG, Boehringer-Ingelheim, Bristol-Myers Squibb Company, Daiichi Sankyo Co. Ltd., Mylan N.V., Novartis AG, Par Pharmaceutical Companies Inc., Pfizer Inc
Key Market Drivers	Increasing research and development activities for safe drug development

Buy Now Full Report @ https://straitsresearch.com/buy-now/myocardial-infarction-market

Asia Pacific is the fastest-growing region in the forecast period

Myocardial infarction is one of the major diseases in China. It has become the major cause of an emergency over the past few decades owing to changing lifestyle and declining physical activity. In China, of men aged 30–44 years who die from cardiovascular disease, 46% of these deaths are attributable to tobacco. Additionally, there are more than 300 million smokers in China, nearly one-third of the world’s total smoking population. This is projected to increase the risk of developing cardiovascular diseases, which is also expected to increase the demand for their demand. Thus, China is projected to witness considerable growth in the market during the forecast period.

Competitive Landscape

Daiichi Sankyo, Co. Ltd is one of the leading providers of the medical solution of various segments including cardiovascular diseases such as myocardial infarction or heart attack and angina, kidney disease, and oncology segment across the globe. The company is differentiating itself with continuous innovations and expansion in various regions. Several products such as Efient and Ovisot have been launched by the company for the treatment of heart diseases over the last few years. The products have helped the company to strengthen its position in the market and also, to expand their product portfolio related to heart attack and other diseases.

Some of the prominent players in the market are

Apotex Inc.
AstraZeneca
Bayer AG
Boehringer-Ingelheim
Bristol-Myers Squibb Company
Daiichi Sankyo Co. Ltd.
Mylan N.V.
Novartis AG
Par Pharmaceutical Companies Inc.
Pfizer Inc.

Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/myocardial-infarction-market/request-sample

Global Myocardial Infarction Market Segmentation

By Product Type

Analgesics
Antiplatelet agents
Vasodilators
Thrombolytics and anti-thrombotic agents
Glycoprotein IIb/IIIa inhibitors
Β adrenergic blockers
Angiotensin receptor antagonists
Angiotensin converting enzyme inhibitors

By Distribution channel

Hospitals
Hospital Pharmacies
Drug Stores
Online drug stores

Regions Covered

North America
South America

Western Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
Eastern Europe

China
India
Japan
South Korea
Australia
Rest of Asia-Pacific

Middle East
- Saudi Arabia
- UAE
- Qatar
- Rest of The Middle East
Africa

Table of Contents

Executive Summary
Research Scope & Segmentation
1. Research Objectives
2. Market Definition
3. Limitations & Assumptions
4. Market Scope & Segmentation
5. Currency & Pricing Considered
Market Opportunity Assessment
1. Emerging Regions / Countries
2. Emerging Companies
3. Emerging Applications / End Use
4. Investment Landscape
5. New Business Models / Revenue Streams
6. TAM
Market Trends
1. Drivers
2. Market Warning Factors
3. Latest Macro Economic Indicators
4. Geopolitical Impact
5. Human Factors
6. Technology Factors
Market Assessment
1. Porters Five Forces Analysis
2. Value Chain Analysis
3. Sales And Distribution Channel Analysis
4. Case Study Analysis
5. Patent Analysis
6. M & A Agreements & Collabration Analysis
ESG Trends
Global Myocardial Infarction Market Size Analysis
1. Global Myocardial Infarction Market Introduction
2. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Analgesics
    1. By Value
  3. Antiplatelet Agents
    1. By Value
  4. Vasodilators
    1. By Value
  5. Thrombolytics And Anti-Thrombotic Agents
    1. By Value
  6. Glycoprotein IIb/IIIa Inhibitors
    1. By Value
  7. Β Adrenergic Blockers
    1. By Value
  8. Angiotensin Receptor Antagonists
    1. By Value
  9. Angiotensin Converting Enzyme Inhibitors
    1. By Value
3. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospitals
    1. By Value
  3. Hospital Pharmacies
    1. By Value
  4. Drug Stores
    1. By Value
  5. Online Drug Stores
    1. By Value
North America Market Analysis
1. Introduction
2. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Analgesics
    1. By Value
  3. Antiplatelet Agents
    1. By Value
  4. Vasodilators
    1. By Value
  5. Thrombolytics And Anti-Thrombotic Agents
    1. By Value
  6. Glycoprotein IIb/IIIa Inhibitors
    1. By Value
  7. Β Adrenergic Blockers
    1. By Value
  8. Angiotensin Receptor Antagonists
    1. By Value
  9. Angiotensin Converting Enzyme Inhibitors
    1. By Value
3. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospitals
    1. By Value
  3. Hospital Pharmacies
    1. By Value
  4. Drug Stores
    1. By Value
  5. Online Drug Stores
    1. By Value
4. U.S.
  1. By Product Type
    1. Introduction
      1. Product Type By Value
    2. Analgesics
      1. By Value
    3. Antiplatelet Agents
      1. By Value
    4. Vasodilators
      1. By Value
    5. Thrombolytics And Anti-Thrombotic Agents
      1. By Value
    6. Glycoprotein IIb/IIIa Inhibitors
      1. By Value
    7. Β Adrenergic Blockers
      1. By Value
    8. Angiotensin Receptor Antagonists
      1. By Value
    9. Angiotensin Converting Enzyme Inhibitors
      1. By Value
  2. By Distribution Channel
    1. Introduction
      1. Distribution Channel By Value
    2. Hospitals
      1. By Value
    3. Hospital Pharmacies
      1. By Value
    4. Drug Stores
      1. By Value
    5. Online Drug Stores
      1. By Value
5. Canada
Europe Market Analysis
1. Introduction
2. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Analgesics
    1. By Value
  3. Antiplatelet Agents
    1. By Value
  4. Vasodilators
    1. By Value
  5. Thrombolytics And Anti-Thrombotic Agents
    1. By Value
  6. Glycoprotein IIb/IIIa Inhibitors
    1. By Value
  7. Β Adrenergic Blockers
    1. By Value
  8. Angiotensin Receptor Antagonists
    1. By Value
  9. Angiotensin Converting Enzyme Inhibitors
    1. By Value
3. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospitals
    1. By Value
  3. Hospital Pharmacies
    1. By Value
  4. Drug Stores
    1. By Value
  5. Online Drug Stores
    1. By Value
4. U.K.
  1. By Product Type
    1. Introduction
      1. Product Type By Value
    2. Analgesics
      1. By Value
    3. Antiplatelet Agents
      1. By Value
    4. Vasodilators
      1. By Value
    5. Thrombolytics And Anti-Thrombotic Agents
      1. By Value
    6. Glycoprotein IIb/IIIa Inhibitors
      1. By Value
    7. Β Adrenergic Blockers
      1. By Value
    8. Angiotensin Receptor Antagonists
      1. By Value
    9. Angiotensin Converting Enzyme Inhibitors
      1. By Value
  2. By Distribution Channel
    1. Introduction
      1. Distribution Channel By Value
    2. Hospitals
      1. By Value
    3. Hospital Pharmacies
      1. By Value
    4. Drug Stores
      1. By Value
    5. Online Drug Stores
      1. By Value
5. Germany
6. France
7. Spain
8. Italy
9. Russia
10. Nordic
11. Benelux
12. Rest Of Europe
Apac Market Analysis
1. Introduction
2. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Analgesics
    1. By Value
  3. Antiplatelet Agents
    1. By Value
  4. Vasodilators
    1. By Value
  5. Thrombolytics And Anti-Thrombotic Agents
    1. By Value
  6. Glycoprotein IIb/IIIa Inhibitors
    1. By Value
  7. Β Adrenergic Blockers
    1. By Value
  8. Angiotensin Receptor Antagonists
    1. By Value
  9. Angiotensin Converting Enzyme Inhibitors
    1. By Value
3. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospitals
    1. By Value
  3. Hospital Pharmacies
    1. By Value
  4. Drug Stores
    1. By Value
  5. Online Drug Stores
    1. By Value
4. China
  1. By Product Type
    1. Introduction
      1. Product Type By Value
    2. Analgesics
      1. By Value
    3. Antiplatelet Agents
      1. By Value
    4. Vasodilators
      1. By Value
    5. Thrombolytics And Anti-Thrombotic Agents
      1. By Value
    6. Glycoprotein IIb/IIIa Inhibitors
      1. By Value
    7. Β Adrenergic Blockers
      1. By Value
    8. Angiotensin Receptor Antagonists
      1. By Value
    9. Angiotensin Converting Enzyme Inhibitors
      1. By Value
  2. By Distribution Channel
    1. Introduction
      1. Distribution Channel By Value
    2. Hospitals
      1. By Value
    3. Hospital Pharmacies
      1. By Value
    4. Drug Stores
      1. By Value
    5. Online Drug Stores
      1. By Value
5. Korea
6. Japan
7. India
8. Australia
9. Taiwan
10. South East Asia
11. Rest Of Asia-Pacific
Middle East And Africa Market Analysis
1. Introduction
2. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Analgesics
    1. By Value
  3. Antiplatelet Agents
    1. By Value
  4. Vasodilators
    1. By Value
  5. Thrombolytics And Anti-Thrombotic Agents
    1. By Value
  6. Glycoprotein IIb/IIIa Inhibitors
    1. By Value
  7. Β Adrenergic Blockers
    1. By Value
  8. Angiotensin Receptor Antagonists
    1. By Value
  9. Angiotensin Converting Enzyme Inhibitors
    1. By Value
3. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospitals
    1. By Value
  3. Hospital Pharmacies
    1. By Value
  4. Drug Stores
    1. By Value
  5. Online Drug Stores
    1. By Value
4. UAE
  1. By Product Type
    1. Introduction
      1. Product Type By Value
    2. Analgesics
      1. By Value
    3. Antiplatelet Agents
      1. By Value
    4. Vasodilators
      1. By Value
    5. Thrombolytics And Anti-Thrombotic Agents
      1. By Value
    6. Glycoprotein IIb/IIIa Inhibitors
      1. By Value
    7. Β Adrenergic Blockers
      1. By Value
    8. Angiotensin Receptor Antagonists
      1. By Value
    9. Angiotensin Converting Enzyme Inhibitors
      1. By Value
  2. By Distribution Channel
    1. Introduction
      1. Distribution Channel By Value
    2. Hospitals
      1. By Value
    3. Hospital Pharmacies
      1. By Value
    4. Drug Stores
      1. By Value
    5. Online Drug Stores
      1. By Value
5. Turkey
6. Saudi Arabia
7. South Africa
8. Egypt
9. Nigeria
10. Rest Of MEA
LATAM Market Analysis
1. Introduction
2. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Analgesics
    1. By Value
  3. Antiplatelet Agents
    1. By Value
  4. Vasodilators
    1. By Value
  5. Thrombolytics And Anti-Thrombotic Agents
    1. By Value
  6. Glycoprotein IIb/IIIa Inhibitors
    1. By Value
  7. Β Adrenergic Blockers
    1. By Value
  8. Angiotensin Receptor Antagonists
    1. By Value
  9. Angiotensin Converting Enzyme Inhibitors
    1. By Value
3. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospitals
    1. By Value
  3. Hospital Pharmacies
    1. By Value
  4. Drug Stores
    1. By Value
  5. Online Drug Stores
    1. By Value
4. Brazil
  1. By Product Type
    1. Introduction
      1. Product Type By Value
    2. Analgesics
      1. By Value
    3. Antiplatelet Agents
      1. By Value
    4. Vasodilators
      1. By Value
    5. Thrombolytics And Anti-Thrombotic Agents
      1. By Value
    6. Glycoprotein IIb/IIIa Inhibitors
      1. By Value
    7. Β Adrenergic Blockers
      1. By Value
    8. Angiotensin Receptor Antagonists
      1. By Value
    9. Angiotensin Converting Enzyme Inhibitors
      1. By Value
  2. By Distribution Channel
    1. Introduction
      1. Distribution Channel By Value
    2. Hospitals
      1. By Value
    3. Hospital Pharmacies
      1. By Value
    4. Drug Stores
      1. By Value
    5. Online Drug Stores
      1. By Value
5. Mexico
6. Argentina
7. Chile
8. Colombia
9. Rest Of LATAM
Competitive Assessment
1. Adoption Matrix
2. Myocardial Infarction Market Share By Manufacturers
3. Myocardial Infarction Market Ranking By Revenue For Manufacturers
4. Average Price By Manufacturers
5. Vendor Footprint Analysis
Market Players Assessment
1. Apotex Inc.
  1. Overview
  2. Business Information
  3. Revenue
  4. ASP
  5. Gross Margin
  6. Swot Analysis
  7. Recent Developmments
2. AstraZeneca
3. Bayer AG
4. Boehringer-Ingelheim
5. Bristol-Myers Squibb Company
6. Daiichi Sankyo Co. Ltd.
7. Mylan N.V.
8. Novartis AG
9. Par Pharmaceutical Companies Inc.
10. Pfizer Inc.
Research Methodology
1. Research Data
  1. Secondary Data
    1. Major Secondary Sources
    2. Key Data From Secondary Sources
  2. Primary Data
    1. Key Data From Primary Sources
    2. Breakdown Of Primaries
  3. Secondary And Primary Research
    1. Key Industry Insights
2. Market Size Estimation
  1. Bottom-Up Approach
  2. Top-Down Approach
  3. Market Projection
3. Research Assumptions
  1. Assumptions
4. Limitations
5. Risk Assessment
APPENDIX
1. Discussion Guide
2. Customization Options
3. Related Reports
DISCLAIMER

Table of Content @ https://straitsresearch.com/report/myocardial-infarction-market/toc

News Media

Myocardial Infarction Market was Valued at USD 1,530.7 million in 2018, at a CAGR of 8.0%.

Have a Look at the Related Research Report

Cardiovascular Ultrasound (CVUS) Market: Information by Type (Transthoracic Echocardiography), Technology (2D, 3D/4D, Doppler (Display: B/W, Color)), End-Use, and Region – Forecast till 2030

Cardiovascular Needle Market: Information by Type (Round-bodied needles, Cutting needles), Application (Open heart surgery, Cardiac valve procedures), and Region- Forecast till 2030

Heart Pump Device Market: Information by Product (Ventricular Assist Devices, Intra-Aortic Balloon Pumps), Type (Implantable Heart Pump Devices), Therapy, and Region — Forecast till 2031

Coronary Heart Disease Diagnostic Imaging Devices Market: Information by Modality (Computed Tomography, X rays), and Region- Forecast till 2030

About Straits Research Pvt. Ltd.

Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision-making and ROI.

Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client’s purchase. We overcome our clients’ issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.

For more information on your target market, please contact us below:

Phone: +1 646 480 7505 (the U.S.)

+91 8087085354 (APAC)

+44 208 068 9665 (the U.K.)

Email: [email protected]

Follow Us: LinkedIn | Facebook | Instagram | Twitter

Stay connected with us on social media platform for instant update click here to join our T witter, & Facebook

We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.

For all the latest Health News Click Here

For the latest news and updates, follow us on Google News.

Read original article here

Denial of responsibility! NewsAzi is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.